Fidelity Investments, a renowned investment management company, recently shared insights from its “Fidelity Growth Strategies Fund” fourth-quarter 2025 investor letter. This fund focuses on diversified equity strategies within the domestic midcap growth stocks sector, aiming to identify quality companies with steady above-average growth potential. The Fund returned -3.44% in the last quarter, outperforming the benchmark Russell Midcap® Growth Index’s -3.70% return.
In the fourth quarter of 2025, the U.S. stock market experienced a rapid rebound, driven by strong corporate fundamentals and increased spending on artificial intelligence. While large-cap stocks benefited from companies connected to generative AI, mid-cap growth stocks underperformed. As the new year, 2026, unfolds, Fidelity Investments remains optimistic about the positive business cycles in the U.S. and globally, focusing on companies with durable competitive advantages and growth potential.
One of the highlighted companies in Fidelity’s investor letter is IDEXX Laboratories, Inc. (NASDAQ:IDXX). This U.S.-based healthcare company specializes in manufacturing products for various industries, including veterinary, livestock, poultry, dairy, and water testing. With a market capitalization of $51.438 billion, IDEXX Laboratories, Inc. (NASDAQ:IDXX) saw its stock close at $642.94 per share on February 4, 2026. While the stock delivered a -9.75% return in the past month, it has shown significant growth, with a 39.60% increase over the past twelve months.
Fidelity Growth Strategies Fund expressed its views on IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the investor letter, stating that the company’s recent growth may not be sustainable in the long term. While IDEXX is considered a solid and consistent business with strong quarterly results, Fidelity prefers other investments in the mid-cap growth universe.
Despite IDEXX Laboratories, Inc. (NASDAQ:IDXX) not being among the 30 most popular stocks among hedge funds, 55 hedge fund portfolios held shares of the company at the end of the third quarter. Fidelity acknowledges the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment but believes that certain AI stocks offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks poised to benefit from current market trends, Fidelity suggests exploring their free report on the best short-term AI stock.
Overall, Fidelity Growth Strategies Fund continues to navigate the ever-evolving investment landscape by focusing on companies with strong growth prospects and competitive advantages. Their investor letter serves as a guide for investors looking to make informed decisions in the dynamic market environment.
